 |
|
| Blog results | Results 1 - 10 of about 323 for takeda lansoprazole. (0.18 seconds) |
| Sorted by relevance Sort by date |
| 24 Nov 2009 Discovered by Takeda, lansoprazole is a proton pump inhibitor which was launched in Japan in 1992, with the already approved indications including gastric ulcer, duodenal ulcer and reflux esophagitis. NSAIDs are mainly prescribed for ... Takeda Pharmaceutical Company Limited - http://www.takeda.com/ [ More results from Takeda Pharmaceutical Company Limited ] |
| 20 Nov 2009 by Dr DK Sarwal Innovator Takeda has appealed against the U.S. District Court for the District of Delaware decision, wherein, court found no infringement by Teva in a patent dispute on Lansoprazole (Prevacid) ODT tablets. ... IP Pharma Doc - http://ippharmdoc.blogspot.com/ [ More results from IP Pharma Doc ] |
| 26 Nov 2009 Takeda has submitted an application in Japan for the approval of Takepron (lansoprazole) for the prevention of gastric and duodenal ulcers associated with the use of non-steroidal anti-inflammatory drugs (NSAIDs). Scrip News - Home - RSS - http://www.scripnews.com/home/ [ More results from Scrip News - Home - RSS ] |
| 2 Dec 2009 by Vakily, M., Wu, J., Atkinson, SN From Takeda Global Research & Development Center, Inc, Lake Forest, Illinois (TAP Pharmaceutical Products, Inc, Lake Forest, Illinois, is now a part of Takeda Global Research & Development Center, Inc). The effect of the proton pump inhibitor dexlansoprazole, an enantiomer of lansoprazole, on QT intervals was assessed after oral administration of a modified-release formulation of dexlansoprazole (dexlansoprazole MR). In this randomized, positive-comparator, ... The Journal of Clinical Pharmacology current issue - http://jcp.sagepub.com/ |
| 17 Dec 2009 by Maggie Guo KAPIDEX combines an enantiomer of lansoprazole with a Dual Delayed Release(TM) (DDR) formulation designed to provide two separate releases of medication. KAPIDEX, taken once daily, is approved for the healing of all grades of erosive esophagitis (EE) for ... neurology and other conditions. Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. – Takeda Pharmaceuticals North America, Inc ... zikkir - http://zikkir.com/health/ |
| 10 Nov 2009 by admin ... District of Delaware has issued a decision in its litigation over the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Takeda Pharmaceuticals North America, Inc.'s Prevacid® (Lansoprazole) SoluTab. ... Medical News Base - http://www.medicalnewsbase.com/ |
| 13 Nov 2009 by aquinlan@morrisjames.com (Amy A. Quinlan) Plaintiff holds the NDA for lansoprazole delayed released tablets marketed as PREVACID®Solutab™. A bench trial was held from March 9 – 10, 2009 to determine whether the accused ANDA products infringe claim 1 of the '632 patent. ... Delaware Patent Litigation Report - http://depatentlaw.morrisjames.com/ |
| 29 Oct 2009 by Livingstonklqt KAPIDEX combines an enantiomer of lansoprazole with a Dual Delayed Release(TM) (DDR) formulation designed to provide two separate releases of medication. SOURCE online pharmacies list Takeda Pharmaceuticals North America, Inc. ... Walrecht Family Project - Recent changes [en] - http://www.walrecht.info/w/Main_Page |
| 24 Nov 2009 ... (LOAD) given for 7 or 10 days eradicated the bacterium in 95% of patients compared with an 81% eradication rate for the standard 10-day three-drug regimen of lansoprazole (Prevacid—Takeda), amoxicillin, and clarithromycin (LAC). ... American Pharmacists Association - http://www.pharmacist.com/ [ More results from American Pharmacists Association ] |
| 6 Oct 2008 TAK-390MR Data Presented at the American College of Gastroenterology Annual Meeting Combined results from two Phase 3 studies presented at the American College. Drugs.com - Clinical Trials - http://www.drugs.com/clinical_trials.html [ More results from Drugs.com - Clinical Trials ] |
Stay up to date on these results:
| Google Home - About Google Blog Search Beta - Information for Blog Authors |
